About AFYREN
AFYREN is a company based in Paris (France) founded in 2012 by Jeremy Pessiot, Regis Nouaille, and Nicolas Sordet.. AFYREN has raised $25.59 million across 5 funding rounds from investors including Bpifrance, Valquest Capital Management and Sofinnova Partners. AFYREN offers products and services including Biobased Acetic Acid, Biobased Propionic Acid, and Biobased Butyric Acid. AFYREN operates in a competitive market with competitors including Spore Biotechnologies, Biopsin, Mesosil, Celsis and Source Molecular, among others.
- Headquarter Paris, France
- Founders Jeremy Pessiot, Regis Nouaille, Nicolas Sordet
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Afyren Sas
-
Annual Revenue
$2.97 M (USD)-15.3as on Dec 31, 2024
-
Net Profit
$-10.13 M (USD)-1.75as on Dec 31, 2024
-
EBITDA
$-6.13 M (USD)-4.54as on Dec 31, 2024
-
Total Equity Funding
$25.59 M (USD)
in 5 rounds
-
Latest Funding Round
$26.55 M (USD), Post-IPO
Nov 26, 2025
-
Investors
Bpifrance
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of AFYREN
AFYREN is a publicly listed company on the EURONEXT with ticker symbol ALAFY in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of AFYREN
AFYREN offers a comprehensive portfolio of products and services, including Biobased Acetic Acid, Biobased Propionic Acid, and Biobased Butyric Acid. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Fermentation-derived acid replacing petroleum-based versions in industries.
Biobased acid for use in feed and food preservation applications.
Sustainable acid applied in flavors and functional fluids sectors.
Unlock access to complete
Unlock access to complete
Funding Insights of AFYREN
AFYREN has successfully raised a total of $25.59M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $26.55 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $26.6M
-
First Round
First Round
(14 Oct 2015)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2025 | Amount | Post-IPO - AFYREN | Valuation | Kemin |
|
| Jul, 2025 | Amount | Grant - AFYREN | Valuation |
investors |
|
| Feb, 2019 | Amount | Series A - AFYREN | Valuation | Valquest Capital Management , Sofinnova Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AFYREN
AFYREN has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Bpifrance, Valquest Capital Management and Sofinnova Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Founded Year | Domain | Location | |
|
Financial support is provided for SMEs and startups in Auvergne.
|
Founded Year | Domain | Location | |
|
Provides comprehensive merger and acquisition services, business valuations, and other solutions for the investment industry.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AFYREN
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - AFYREN
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Afyren Comparisons
Competitors of AFYREN
AFYREN operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spore Biotechnologies, Biopsin, Mesosil, Celsis and Source Molecular, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Microbial detection technology is developed for life science industries.
|
|
| domain | founded_year | HQ Location |
Real-time microbial detection system is developed for product testing.
|
|
| domain | founded_year | HQ Location |
Antimicrobial materials are developed for infection prevention in medical devices.
|
|
| domain | founded_year | HQ Location |
Rapid microbial screening systems are manufactured for quality control testing.
|
|
| domain | founded_year | HQ Location |
Technology for microbial source tracking is provided by Source Molecular.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Afyren
Frequently Asked Questions about AFYREN
When was AFYREN founded?
AFYREN was founded in 2012 and raised its 1st funding round 3 years after it was founded.
Where is AFYREN located?
AFYREN is headquartered in Paris, France.
Who is the current CEO of AFYREN?
Nicolas Sordet is the current CEO of AFYREN. They have also founded this company.
Is AFYREN a funded company?
AFYREN is a funded company, having raised a total of $25.59M across 5 funding rounds to date. The company's 1st funding round was a Series A of $23.73M, raised on Oct 14, 2015.
What is the annual revenue of AFYREN?
Annual revenue of AFYREN is $2.97M as on Dec 31, 2024.
What does AFYREN do?
AFYREN was founded in 2012 and is based in Paris, France. Operations focus on the biotechnology sector, where analytical services are delivered for microbiology, chemistry, and bioprocesses industries. The Afynerie technology is utilized to convert non-food biomass wastes into high-value biomolecules. Services encompass measurements of methane or biogas production from organic substrate degradation by anaerobic microorganisms, alongside physicochemical characterization of organic substrates.
Who are the top competitors of AFYREN?
AFYREN's top competitors include Spore Biotechnologies, NCIMB and Biopsin.
What products or services does AFYREN offer?
AFYREN offers Biobased Acetic Acid, Biobased Propionic Acid, and Biobased Butyric Acid.
Is AFYREN publicly traded?
Yes, AFYREN is publicly traded on EURONEXT under the ticker symbol ALAFY.
Who are AFYREN's investors?
AFYREN has 5 investors. Key investors include Bpifrance, Valquest Capital Management, Sofinnova Partners, JEREMIE Auvergne, and Kemin.
What is AFYREN's ticker symbol?
The ticker symbol of AFYREN is ALAFY on EURONEXT.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.